Dependence on Drug Sales Performance: Royalty Pharma's revenue is directly tied to the sales performance of the biopharmaceutical products on which they hold royalty interests. Underperformance due to market competition, safety issues, manufacturing problems, or physician reluctance could significantly reduce their cash flows.

Clinical Trial and Regulatory Failure Risk: A substantial portion of their investments are in late-stage development programs. Failure of these programs in clinical trials or inability to secure regulatory approval would mean the anticipated future royalty streams will not materialize, resulting in significant losses on their investments.

Intellectual Property Challenges and Expiry: The value of their royalty interests is dependent on the underlying patents and intellectual property rights. Challenges to these patents, or their expiration, could lead to generic competition, reduced pricing power, and a substantial decrease in royalty income.